Navigation Links
Treatment of First Patient in Phase I Clinical Trial of Bionomics' Anti-Cancer Drug BNC105
Date:2/25/2008

MELBOURNE, Australia, Feb. 26 /PRNewswire/ -- Bionomics Limited (ASX: BNO) today announced the initiation of treatment for the first patient in the Phase I trial of its anti-cancer drug, BNC105.

The BNC105 Phase I clinical trial involves treatment of patients with advanced cancer. Patients will be treated with BNC105 on days 1 and 8 of a 21 day cycle, over two cycles. The trial will be conducted at clinical sites within the Cancer Trials Australia network at the Royal Melbourne Hospital, the Peter MaCallum Cancer Centre and the Western Hospital in Melbourne.

Dr. Deborah Rathjen, CEO and Managing Director of Bionomics hailed the commencement of the Phase I trial as a significant milestone for the Company.

"We are excited to commence our trial of BNC105 and to announce our first patient has begun treatment," Dr Rathjen commented. "We will provide regular updates as we move through the trial, and I look forward to updating shareholders on our progress."

The primary objective for this trial is the evaluation of the safety and tolerability of BNC105. The results obtained from this trial will enable the identification of an appropriate dose of BNC105 for subsequent trials. Further objectives include, the evaluation of BNC105 pharmacokinetics and its activity against tumour vasculature and tumour growth.

BNC105 is a new type of anti-cancer drug called a Vascular Disruption Agent (VDA) which blocks the blood supply to a solid tumour, effectively "starving" the tumour of nutrients. Pre-clinical data indicates that BNC105 has a dual mechanism of action with the ability to not only block the supply of nutrients to the tumour but also to directly destroy cancer cells. In addition, BNC105 is retained in the tumour at high levels for an extended period of time, enhancing its' anti-cancer effect.

Although VDAs have strong potential for use in combination with traditional cancer treatment options, including chemotherapy, preclinical
'/>"/>

SOURCE Bionomics Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... and Markets ( http://www.researchandmarkets.com/research/x5lz9r/global_poc ) has announced ... 2015-2019" report to their offering. , ... to grow at a CAGR of 8.47 percent over ... IVD devices and tools used for diagnosing diseases in ... these devices helps in the rapid diagnosis of the ...
(Date:3/3/2015)... , March 3, 2015  Michigan brothers Dominique Larkin ... called arrhythmogenic right ventricular dysplasia, or ARVD, a disease that ... sudden death among young athletes. In 2007, doctors ... basketball game. They later tested Dominique and found his "condition ... February 19, 2015 story in The Ann Arbor News ...
(Date:3/3/2015)... 2015  Web Industries, Inc., a leading provider ... Medical Device, Advanced Composites, Consumer Products, and Wire ... Medical Specialties Preferred Converter by 3M,s Medical Specialties ... to streamline their supply chains by using Web ... materials, intermediate converting services, and contract manufacturing and ...
Breaking Medicine Technology:Global POC Diagnostics Market 2015-2019 with Abbott Labs, Alere, Bayer Healthcare, Danaher, F. Hoffmann-La Roche & Johnson & Johnson Dominating 2Younger of 2 Brothers on the SynCardia Total Artificial Heart Gets a Donor Heart Transplant 2Younger of 2 Brothers on the SynCardia Total Artificial Heart Gets a Donor Heart Transplant 3Web Industries Receives 3M Preferred Converter Status 2
... VICTORIA, Australia, April 19, 2011 Genetic Technologies ... executed a preliminary research collaboration agreement to jointly develop ... world,s leading pharmaceutical companies. Under the ... property to work with this world-leading pharmaceutical company to ...
... DALLAS, April 19, 2011 GHX ... Tom Daschle addressed an audience of over 600 healthcare business ... and delivering a sustainable healthcare system at the opening keynote ... The three-day event is focused on the future of the ...
Cached Medicine Technology:GTG Announces New Product Collaboration with Global Pharmaceutical Company for Companion Diagnostics in Oncology 2Getting Healthcare Reform Done with the Entire Supply Chain 2Getting Healthcare Reform Done with the Entire Supply Chain 3Getting Healthcare Reform Done with the Entire Supply Chain 4
(Date:3/3/2015)... (PRWEB) March 04, 2015 As payers ... value-based payment contracts within the next few years, they ... the significant chunk of health care spending they control ... Inc.’s ACO Business News (ABN) tracks some of ... of a commercial accountable care organization (ACO)-type model. , ...
(Date:3/3/2015)... Calif. (PRWEB) March 03, 2015 ... provider of enterprise Time and Attendance / Workforce ... migrated to NOVAtime SaaS Workforce Management / ... time and attendance processes. , Since 2004, ... with developmental disabilities with the best quality of ...
(Date:3/3/2015)... Loma Linda, CA (PRWEB) March 03, 2015 ... its commitment to whole health and well being, it ... its vending machines across its campuses. , Over the ... nutritional leadership took part in creating dietary criteria, listening ... single vendor for the entire organization. , Most ...
(Date:3/3/2015)... Findings could lead to better therapies ... have developed and characterized a molecule that interferes with ... self-destruct. This novel mechanism was found to be effective ... type of brain cancer – and could be applicable ... to be published in the April 2015 issue of ...
(Date:3/3/2015)... 03, 2015 Dan E. Chambers, an experienced ... focus on capital crimes, recently spoke on the radio to ... The hosts of the Independent Journal Review radio show “The ... first as a prosecutor and now as a criminal defense ... made in the trial and sentencing of this high-profile case. ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Examines Ways to Engage Specialists in Value-Based Payment Contracts 2Health News:AIS Newsletter Examines Ways to Engage Specialists in Value-Based Payment Contracts 3Health News:Innovative Services, Inc. Successfully Migrates to Cloud-Based NOVAtime Workforce Management Solution to Support Growth and Improve Payroll Processing Time 2Health News:Innovative Services, Inc. Successfully Migrates to Cloud-Based NOVAtime Workforce Management Solution to Support Growth and Improve Payroll Processing Time 3Health News:Loma Linda University Health Rejuvenates Its Vending Machines with Healthier Selections 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 3Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 4Health News:Dan E. Chambers Gives Radio Interview Providing Insights into American Sniper Guilty Verdict 2Health News:Dan E. Chambers Gives Radio Interview Providing Insights into American Sniper Guilty Verdict 3
... 22 MUSCLEPHARM(R) LLC, the rising star of the ... product launch through each of Vitamin Shoppe,s 400+ locations ... this nationwide launch of our entire line of products," ... available to athletes in nearly every neighborhood across the ...
... Platform in the Bone Graft Market , , MOUNTAIN ... the bone graft market, Frost & Sullivan recognizes Bone Solutions, ... for Technology Leadership of the Year for its development of ... ligaments and tendons to bone and bone-to-bone. On May ...
... In Generics, There Is No Clear Evidence of Expanded Uptake ... from Decision Resources , , Patient-Flow Forecasts Need to ... of Therapy Over the Next Two Years , ... the world,s leading research and advisory firms focusing on pharmaceutical ...
... University Children,s Hospital Zurich has achieved a world ... patients have been successfully treated by means of ... opens new horizons for neurosurgery and the treatment ... context of a clinical study at the MR ...
... and Anthropology at the University of Haifa presented the ... conference held at the University of Haifa. , The ... silent and non-pathological expression in the everyday lives of ... past suffices for their children Aspects of ...
... Pilot program kicks off in Northwestern PA , , ... pregnant smokers about the harms of tobacco use on their ... Pennsylvania (NWPA) Tobacco Control Program are launching a new smoking ... who smoke in that region of the state. , ...
Cached Medicine News:Health News:MUSCLEPHARM Products Hit Vitamin Shoppe Shelves With a Bang! 2Health News:Frost & Sullivan Selects Bone Solutions for Technology Leadership of the Year Award 2Health News:Frost & Sullivan Selects Bone Solutions for Technology Leadership of the Year Award 3Health News:Frost & Sullivan Selects Bone Solutions for Technology Leadership of the Year Award 4Health News:Seroquel's First- and Second-Line Patient Share Has Grown Since Last Year's Analysis of Prescribing Trends in Bipolar Disorder 2Health News:Seroquel's First- and Second-Line Patient Share Has Grown Since Last Year's Analysis of Prescribing Trends in Bipolar Disorder 3Health News:Successful neurosurgery with transcranial MR-guided high-intensity focused ultrasound 2Health News:Successful neurosurgery with transcranial MR-guided high-intensity focused ultrasound 3Health News:Unspoken memories of Holocaust survivors find silent and nonpathological expression 2Health News:State Launches New Campaign to Help Pregnant Smokers Go Tobacco-Free 2
... is our most popular Low ... It offers a wide field ... and hence a slightly shorter ... be mounted to virtually and ...
This 6x or 8x aspheric magnifier is fitted with a distance piece and is particularly useful for patients with tremor or focusing difficulties. The magnifier can be either spectacle mounted or hand h...
This full segment bifocal can be screwed into a hole in a corrective or plano lens, or mounted directly on top of a prescription lens....
All Keeler magnifiers and telescope are available on a clip to fit over the patient's own spectacle...
Medicine Products: